Abstract

Introduction: There is an increasing risk of mucormycosis in the post Covid patients, especially in the second wave of the pandemic, there has been a tremendous rise of mucormycosis in covid 19 cases, therby increasing the mortality and morbidity. There are many risk factors contributing to mucor among which diabetes mellitus is seen as an independant and most common risk factor.
Aims and Objectives: To study the clinical manifestations, treatment ,mortality and mortality of mucormycosis in covid 19.
Materials and Methods: This is an observational study carried out between April 2021 to june 2021. This study observes the clinical manifestations and CT findings, treatment and outcomes in 25 patients of mucormycosis.
Observation: This study included a total 25 patients of which 21(84%) are male and 4(16%) are female. The age of the patients varied between 25 -60 years with 49 years being the mean age group.
Out of 25 members ,20 have diabetes, 1 has hypertension, 3 have hypothyroidism, 6 are smokers, 2 have coronary artery disease and are alcoholics. 24 underwent FESS and debridement and were treated with Amphotericin B and posaconazole. And 23 out of 25 used steroids.
2 of the 25 members died of severe mucor out of which 1 died before surgery and 1 after surgery
Conclusion: In this study it has been observed that the early diagnosis and treatment of mucormycosis with better control of diabetes leads to improvement of mortality and morbidity in these patients.

Key words: covid 19, mucormycosis, steroids, FESS